---
title: "开拓药业有限公司 (09939.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/09939.HK.md"
symbol: "09939.HK"
name: "开拓药业有限公司"
industry: "生物技术"
---

# 开拓药业有限公司 (09939.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 港股市场 |
| Website | [www.kintor.com.cn](https://www.kintor.com.cn) |

## Company Profile

开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科 (如脱发、痤疮等) 及肿瘤适应症。该公司在皮科领域有两款核心药物 KX-826 及 GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌 (mCRPC)、肝癌、特发性肺纤维化、恶性血液疾病及多种实体肿瘤等。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:10.000Z

**Overall: D (0.70)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 44 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 81.82% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.79 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.37B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 11.91M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -54.99% | E |
| Profit Margin | -1521.00% | E |
| Gross Margin | -3.28% | E |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | C |
| Net Profit YoY | 81.82% | A |
| Total Assets YoY | -46.02% | E |
| Net Assets YoY | -43.81% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -6.57% | D |
| OCF YoY | 0.00% | C |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.02 | E |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 44.88% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 开拓药业有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-54.99%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1521.00%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-3.28%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "81.82%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-46.02%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-43.81%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-6.57%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "44.88%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百济神州 (HK.6160) | C | A | B | C | A | B |
| 02 | 信达生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制药 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奥赛图-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和铂医药-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.38 | 29/70 | - | - | - |
| PB | 5.71 | 33/70 | 4.61 | 3.55 | 1.80 |
| PS (TTM) | 112.20 | 54/70 | 126.81 | 101.94 | 83.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2024-10-15T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.71 |

## References

- [Company Overview](https://longbridge.com/en/quote/09939.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/09939.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/09939.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.